PD48-06 DETECTION OF GERMLINE MUTATIONS IN LOCALIZED AND METASTATIC PROSTATE CANCER THROUGH GUIDLINE-BASED TESTING

No evidence of germline PTEN mutations in familial prostate cancer

No evidence of germline PTEN mutations in familial prostate cancer.

No evidence of germline PTEN mutations in familial prostate cancer EDITOR—Prostate cancer is the second most common cause of male cancer mortality in the UK. 1 Current indications are that like many common cancers, prostate cancer has an inherited component. 2 Segregation analysis has led to the proposed model of at least one highly penetrant, dominant gene (with an estimated 88% penetrance for...

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

PURPOSE Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined. EXPERIMENTAL DESIGN We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 ...

Germline Fitness-Based Scoring of Cancer Mutations

A key goal in cancer research is to find the genomic alterations that underlie malignant cells. Genomics has proved successful in identifying somatic variants at a large scale. However, it has become evident that a typical cancer exhibits a heterogenous mutation pattern across samples. Cases where the same alteration is observed repeatedly seem to be the exception rather than the norm. Thus, pi...

hormone therapy in metastatic prostate cancer

only orchiectomy is still commonly used today either as a single therapy or in combination regimens. hypophysectomy & adrenalectomy showed such devastating effects on the endocrine equilibrium as to be inconsistent with an acceptable quality of life or even with survival. chemical adrenalectomy was also tried with drugs (eg. aminoglutethmide, spironolactone) leading to consequences superimposab...